Co-Authors
This is a "connection" page, showing publications co-authored by EKERE ESSIEN and J. THORNTON.
Connection Strength
1.556
-
Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer. J Manag Care Spec Pharm. 2026 Aug; 32(8):979-993.
Score: 0.247
-
The development of a patient-reported outcome measuring opioid use disorder financial toxicity: Establishing content validity and reliability. Drug Alcohol Depend Rep. 2026 Jun; 19:100443.
Score: 0.243
-
Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. Sci Rep. 2026 Apr 04; 16(1).
Score: 0.242
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 12 20; 21(1):220.
Score: 0.221
-
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors. Am J Clin Oncol. 2024 11 01; 47(11):517-525.
Score: 0.214
-
Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors. BMC Cancer. 2023 Jul 13; 23(1):655.
Score: 0.200
-
Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
Score: 0.189